Lipoplex-mediated delivery of siRNAs against CD55, CD46, and CD59 sensitized breast cancer BT474 and SKBR3, ovarian cancer SKOV3, and lung cancer Calu-3 cells to trastuzumab and pertuzumab [185]. The gene discussed is CD55; the disease is breast cancer.